FEB 12, 2020 6:52 PM PST

Diabetic Drug Increasces Risk of Heart Complications

WRITTEN BY: Nouran Amin

A drug by the name of ‘rosiglitazone’ used to treat type 2 diabetes was found to be associated with increased risk of heart problems, especially heart failure. Findings were based on a comprehensive evaluation of the cardiovascular risk from rosiglitazone use.

Rosiglitazone belongs to a class of drugs known as thiazolidinediones that help target blood sugar levels in patients with type 2 diabetes, however, it can also increase the risk of heart complications. As a result, Rosiglitazone use was suspended in Europe and holds previous restrictions in the United States.

Researchers stated: "Our study highlights the need for independent evidence assessment to promote transparency and ensure confidence in approved therapeutics, and postmarket surveillance that tracks known and unknown risks and benefits."

Learn more:

But, since 2007, studies reported conflicting findings about whether rosiglitazone does lead to risky heart complications. These studies did not access raw data from patients and mostly were based on summary level data that was not to the highest reliability. The drug maker of rosiglitazone--GlaxoSmithKline (GSK)--has placed effort to make patient data available for investigators and thus prompted researchers to re-analyze uncertainty about the role of the drug in cardiovascular risk.

"Our study suggests that when evaluating drug safety and performing meta-analyses focused on safety, IPD might be necessary to accurately classify all adverse events," noted the researchers. "By including these data in research, patients, clinicians, and researchers would be able to make more informed decisions about the safety of interventions."

Source: Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUN 23, 2020
Drug Discovery & Development
Psychedelic DMT to Enter Clinical Trials
JUN 23, 2020
Psychedelic DMT to Enter Clinical Trials
Neuro-pharmaceutical company, MindMed, has announced that it will begin a double-blind placebo-controlled Phase 1 clinic ...
JUN 25, 2020
Cannabis Sciences
Can CBD Oil Treat Eczema?
JUN 25, 2020
Can CBD Oil Treat Eczema?
Around 30% of Americans are affected by eczema, a common condition known to cause dry skin, itching, irritation, and inf ...
JUL 02, 2020
Cardiology
Managing the Mitochondria After a Heart Attack
JUL 02, 2020
Managing the Mitochondria After a Heart Attack
Heart attacks are an unfortunately common occurrence across the country. One of the biggest consequences of a heart atta ...
JUL 24, 2020
Cancer
A New Biomarker Candidate for Cancer Diagnostics
JUL 24, 2020
A New Biomarker Candidate for Cancer Diagnostics
One of the best tools in the fight against cancer is diagnostics. In 2018, colorectal cancer was the second most lethal ...
JUL 26, 2020
Cannabis Sciences
Medicinal Cannabis Kills Cancer Cells
JUL 26, 2020
Medicinal Cannabis Kills Cancer Cells
Researchers at the University of Newcastle have found that a modified version of medicinal cannabis can kill and inhibit ...
AUG 04, 2020
Neuroscience
Transcranial Stimulation Disrupts Fearful Memories
AUG 04, 2020
Transcranial Stimulation Disrupts Fearful Memories
Disrupting negative memory formation has been a challenge for years- involving treatments ranging from psychotherapy to ...
Loading Comments...